This webcast contains the most clinically significant information on pancreatic, esophageal, gastric, anal, rectal, hepatocellular, and colorectal cancers, as well as the broader subjects of immune therapy, surgery, and multimodality therapy.
On March 23rd and 24th, 2018, meeting co-chairs Axel Grothey, MD and David Ilson, MD, PhD will join 19 other expert faculty members to discuss colorectal and pancreatic cancers, rare tumors, immunotherapy and hepatobiliary cancers, among other hot topics at the 2018 Great Debates & Updates in GI Malignancies.
At the second annual Oncology Nurse Advisor Navigation Summit (April 7-9, 2016; Orlando, FL), Teresa Labovich, MSN, RN, OCN, Penrose Cancer Center (Colorado Springs, CO), described a method by which gastrointestinal (GI) oncology nurse navigators (ONN) can play a role in improving institutional efficiency and patient outcomes.
Investigating genetic variations within a primary tumor, the differences between the primary tumor and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma (GEA), according to a recent study.
A recent study compared the effects of multiple adjuvant chemoradiotherapy regimens on overall survival (OS) in patients with gastric or gastroesophageal junction adenocarcinoma, published in the Journal of Clinical Oncology (online October 4, 2017; doi:10.1200/JCO.2017.74.2130).
A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017; doi:10.1200/JCO.2016.71.6852).
Administering capecitabine after surgery extends survival by a median of 17 months compared with surgery alone for patients with biliary tract cancer, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).